Abstract:Previous studies have shown that dexmedetomidine exerted anti-inflammatory effect on several animal models with inflammation, but the mechanism is not clear. This study intends to elucidate the anti-inflammatory mechanism of dexmedetomidine through the cholinergic anti-inflammatory pathway. To investigate this therapeutic potential of dexmedetomidine, a murine model of endotoxemia was established induced by lipopolysaccharide (LPS). Animals were assigned to one of four protocols. Protocol one: animals were randomly assigned to control group, dexmedetomidine group, and sterile saline group ( n = 20 each), and these animals were used for survival analysis. The survival rate was assessed up to 120 h after endotoxin injection. Protocol two: animals were randomly assigned to one of four groups ( n = 16 each): group 1 (group Saline), treated with sterile saline 15 min prior to endotoxin treatment (10 mg kg −1 over 2 min); group 2 (group Dex), treated with dexmedetomidine 15 min prior to endotoxin treatment; group 3 (group αBGT + Dex), treated with alpha-7 nicotinic acetylcholine receptors (α7nAChR) antagonist alpha-bungarotoxin (αBGT, 1 μg/kg) 15 min prior to dexmedetomidine treatment; group 4 (group saline + Dex), treated with equivalent sterile saline 15 min prior to dexmedetomidine treatment. Protocol three: animals were randomly assigned to one of two groups ( n = 16 each): vagotomy group (group VNX + Dex), right cervical vagus nerve was exposed and transected; sham-operated group (group SHAM + Dex), the cervical vagus nerve was visualized, but was neither isolated from the surrounding tissues nor transected. Protocol four: animals were treated with dexmedetomidine (40 μg/kg) and sterile saline to observe the discharge activity of cervical vagus nerves by using BL-420F data acquisition and analysis system ( n = 16 each). In the survival analysis groups, the survival rate of dexmedetomidine group was significantly higher than that of the endotoxemia group (65 versus 25 %, P < 0.01). Preemptive administration of dexmedetomidine significantly attenuated the cytokine response after lipopolysaccharide (LPS) induced endotoxemia (TNF-alpha, IL-1beta, IL-6, P < 0.01, respectively). However, preemptive administration of dexmedetomidine failed to suppress cytokine response in α-bungarotoxin group and vagotomy group (TNF-alpha, IL-1beta, IL-6, P > 0.05, respectively). Furthermore, preemptive administration of dexmedetomidine significantly increased the discharge frequency of cervical vagus nerves in comparison with sterile saline treatment ( P < 0.01).Our results demonstrate that the preemptive administration of dexmedetomidine increases the activity of cervical vagus nerve and have the ability to successfully improve survival in experimental endotoxemia by inhibiting the inflammatory cytokines release. However, administration of dexmedetomidine to vagotomy or α7 nAChR antagonist pretreatment mice failed to suppress TNF levels, indicating that the vagus nerve and α7nAChR-mediated cholinergic anti-inflammatory pathway is required for the anti-inflammatory effect of dexmedetomidine. These findings show that central alpha-2 agonist dexmedetomidine suppresses systemic inflammation through vagal- and α7nAChR-dependent mechanism.

Dexmedetomidine inhibits paraventricular corticotropin-releasing hormone neurons that attenuate acute stress-induced anxiety-like behavior in mice

Dexmedetomidine alleviates anxiety-like behavior in mice following peripheral nerve injury by reducing the hyperactivity of glutamatergic neurons in the anterior cingulate cortex

Effects of dexmedetomidine on depression-like behaviour in chronic restraint stress mice: Involvement of specific brain regions

Dexmedetomidine attenuates acute stress-impaired learning and memory in mice by maintaining the homeostasis of intestinal flora

Dexmedetomidine Improves Anxiety-like Behaviors in Sleep-Deprived Mice by Inhibiting the p38/MSK1/NFκB Pathway and Reducing Inflammation and Oxidative Stress

Dexmedetomidine Alleviates Intracerebral Hemorrhage-Induced Anxiety-Like Behaviors in Mice Through the Inhibition of TRPV4 Opening

Dexmedetomidine Improves the Acute Stress Reactivity of Male Rat Through Interventions of Serum- and Glucocorticoid-Inducible Kinase 1 and Nnos in the Bed Nucleus of the Stria Terminalis.

Dexmedetomidine Alleviates Anxiety-Like Behaviors and Cognitive Impairments in a Rat Model of Post-Traumatic Stress Disorder

Dexmedetomidine Exerts an Anti-Inflammatory Effect Via Α2 Adrenoceptors to Alleviate Cognitive Dysfunction in 5xfad Mice.

Effect of Dexmedetomidine on Synaptic Transmission in Spinal Dorsal Horn of Rats

Dexmedetomidine Exerts an Anti-inflammatory Effect via α2 Adrenoceptors to Prevent Lipopolysaccharide-induced Cognitive Decline in Mice.

Dexmedetomidine Alleviates Presurgical Anxiety-Induced Persistent Postsurgical Pain Via Decreasing the Expression of Glucocorticoid Receptor

Dexmedetomidine Ameliorated Cognitive Dysfunction Induced by Intestinal Ischemia Reperfusion in Mice with Possible Relation to the Anti-inflammatory Effect Through the Locus Coeruleus Norepinephrine System

Dexmedetomidine blocks hyperalgesia and dorsal root ganglia ERK signal activation in a rat model of neuropathic pain

Dexmedetomidine Controls Systemic Cytokine Levels Through the Cholinergic Anti-inflammatory Pathway

Dexmedetomidine Attenuates Persistent Postsurgical Pain by Upregulating K+–Cl− Cotransporter-2 in the Spinal Dorsal Horn in Rats

Dexmedetomidine Relieved Neuropathic Pain and Inflammation Response Induced by CCI Through HMGB1/TLR4/NF-κB Signal Pathway.

Effect of dexmedetomidine on rats with chronic neuropathic pain

Dexmedetomidine relieves inflammatory pain by enhancing GABAergic synaptic activity in pyramidal neurons of the anterior cingulate cortex

Regulation of I1-imidazoline receptors on the sedation effect of dexmedetomidine in mice

Dexmedetomidine Exerts an Anti-inflammatory Effect Via Α2 Adrenoceptors to Prevent Lipopolysaccharide-induced Cognitive Decline in Mice